BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20250514T124637EDT-3043wFAmGT@132.216.98.100 DTSTAMP:20250514T164637Z DESCRIPTION:On this page: \n\n\n About the webinar\n Agenda\n Speakers\n\n\n\n \nAbout the webinar\n\nThe success of mRNA vaccines during the COVID-19 pa ndemic has opened the door to a new era in medicine. Today\, advancements in mRNA and lipid nanoparticle (LNP) technologies are paving the way for t he next generation of vaccines and therapeutics -designed to be more poten t\, longer-lasting\, and able to target various diseases.\n\netherna is a technology leader in developing nucleic acid-based medicines\, enabling pa rtners to create unique and novel therapeutics to improve patients’ lives. \n\nJoin ɫTV's D2R Initiative and etherna for an interactive webinar and fireside chat to explore the advancement of mRNA and LNP tech nologies.\n\n\n Innovative mRNA process technology and chemistry to produce ultra-pure\, high-quality mRNA to avoid immunogenicity and ensure safety and efficacy.\n Breakthroughs in LNP technology for diverse therapeutic app lications\; and How to develop these new medicines from concept to the cli nic.\n Compelling data demonstrating etherna's intra-tumoral-stimulatory pl atform that achieves high expression in the tumor while reducing harmful o ff-target expression in the liver of a novel immunomodulation payload lead ing to high antitumor efficacy in preclinical models.\n Detailed case study showcasing the innovation and efficacy of an improved malaria vaccine app roach.\n\n\nFollowed by a panel discussion with renowned faculty from McGi ll University & D2R Initiative along with etherna:\n\n\n Delving into how m RNA and LNP innovations are set to revolutionize medicine and improve coun tless lives.\n The challenges for disease treatment and the opportunities f or therapies beyond vaccine and oncology\n\n\nDon’t miss this opportunity to explore\, learn\, and discuss the groundbreaking innovations in mRNA an d LNP technologies.\n\nRSVP to receive the Zoom link\n\n\n\nAgenda\n\n\n \n \n 12:00\n \n Introductions:\n\n \n Opening Remarks\, by Janet Prince\, D2R\n et herna Company Introduction Overview\, by Ronald Openshaw\, etherna\n \n \n \n \n 12:05\n mRNA Challenges and Solutions – Design\, Manufacture\, Production \, by Phil Challis\, etherna \n \n \n 12:10\n LNP Technology for Diverse Thera peutic Applications\, by Stefaan De Koker\, etherna \n \n \n 12:20\n Case Stud y 1 – Intra-tumoral Platform\, by Florence Lambolez\, etherna \n \n \n 12:30 \n Case Study 2 – Malaria Vaccine Platform\, by Stefaan De Koker\, etherna (12 min)\n \n \n 12:50\n Fireside Chat and Q&A – ɫTVl/etherna\, moderated by Ronald Openshaw (Moderator)\, etherna (20 min)\n \n \n\n\n \n\n\n\n\n\nSpea kers\n\nPhil Challis\, SVP Manufacturing\, etherna\n\nPhil has 30 years of experience in the Pharmaceutical and Biotech industry\, having worked for small SMEs\, larger pharmaceutical companies\, and CDMOs. He has broad ex perience in the manufacture of biologicals and NCEs and expertise in the t ransfer of processes from R&D\, process development through clinical phase s\, process validation\, and commercial manufacture.\n\nStefaan De Koker\, VP Technology and Innovation\, etherna\n\nSteffan is a Principal Scientis t with over 15 years of research experience in immunology\, immuno-oncolog y\, vaccine design\, and nucleic acid delivery. His publication track reco rd includes over 50 publications\, and he is the key author of several pat ents.\n\nFlorence Lambolez\, Director Pharmacology\, etherna\n\nFlorence i s an expert in mucosal T-cell development and function\, having over 20 ye ars of immunology and immuno-oncology experience\, including 7 years of li fe science expertise. Before joining etherna\, Florence was a team leader in in vitro Pharmacology at iTeos Therapeutics and Instructor/Principal In vestigator at La Jolla Institute for Immunology\, San Diego\, US. Florence is widely published and is a holder of several patents.\n\nNathan Luedtke \, Associate Scientific Director\, D2R and Professor\, Chemistry\, ɫTVl \n\nNathan Luedtke’s group pioneered the development of non-toxic\, cataly st-free bioorthogonal “click” reactions on cellular DNA and RNA. In cooper ation with Sigma Aldrich\, the “clickable” nucleosides produced in the Lue dtke Lab have been commercialized and distributed world-wide. This has fac ilitated broad use of Luedtke’s molecules and methods in highly diverse re search fields including biomaterials\, chromosomal architecture\, RNA ther apeutics\, stem cell biology\, virology\, and precision medicine.\n\nJulia Burnier\, Associate Professor\, Pathology\, Oncology\, ɫTVl\n\nDr. Burn ier completed a PhD in molecular and cell biology at ɫTV (Ex perimental Medicine)\, and post-doctoral fellowships at ɫTVl and the Cen tre for Genomic Regulation (Barcelona). Her lab within the Cancer Research Program (CRP) of the RI-MUHC aims to uncover the role and mechanisms of t umor-derived (circulating) molecules in tumor progression and metastasis\, in order to develop novel accurate and sensitive biomarkers and identify new targeted therapeutic strategies. Using liquid biopsy samples and cell models\, she investigates the role of circulating nucleic acids and tumour -derived extracellular vesicles (EVs) in mediating tumour metastasis via c ommunication with and reprograming of the tumor microenvironment. She has developed a unique synthetic system to model EVs and to weaponize them as delivery vehicles for therapeutics.\n\nRonald Openshaw\, Chief Financial O fficer & Head of Commercial\, etherna (moderator)\n\nRonald’s career spans over a dozen years as an investment banker with blue chip firms such as P anmure Gordon\, one of the UK’s oldest City names\, and Jefferies & Co. th e US based investment bank. He also gained great direct industrial experti se in leading Pharmagene plc\, as its CFO and then CEO\, to create Asteran d plc\, a UK London Stock Exchange listed company focused on the core rese arch and tools in translational medicine. Ronald started his career as a s cientist and then qualified as a chartered accountant with KPMG in London. \n DTSTART:20250131T170000Z DTEND:20250131T183000Z LOCATION:Zoom SUMMARY:Industry Insights with etherna URL:/dna-to-rna/channels/event/industry-insights-ether na-362480 END:VEVENT END:VCALENDAR